[
  {
    "ts": null,
    "headline": "5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call",
    "summary": "Vertex Pharmaceuticals encountered a challenging first quarter in 2025, as both revenue and non-GAAP profit fell short of Wall Street expectations, leading to a significant negative market reaction. Management attributed the subdued performance to factors including slower-than-anticipated uptake for newly launched products and specific regional pressures, such as a decline in ex-U.S. cystic fibrosis (CF) revenues due to market dynamics in Russia. CEO Reshma Kewalramani acknowledged, “Russia reve",
    "url": "https://finnhub.io/api/news?id=ebe17f898bab8b72c28e24c55ab9b8dc2cdd81da51904874bd2989c4be84946b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750974656,
      "headline": "5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call",
      "id": 135582170,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals encountered a challenging first quarter in 2025, as both revenue and non-GAAP profit fell short of Wall Street expectations, leading to a significant negative market reaction. Management attributed the subdued performance to factors including slower-than-anticipated uptake for newly launched products and specific regional pressures, such as a decline in ex-U.S. cystic fibrosis (CF) revenues due to market dynamics in Russia. CEO Reshma Kewalramani acknowledged, “Russia reve",
      "url": "https://finnhub.io/api/news?id=ebe17f898bab8b72c28e24c55ab9b8dc2cdd81da51904874bd2989c4be84946b"
    }
  },
  {
    "ts": null,
    "headline": "Procedural Lapses In Indian IP Administration: Vertex Pharmaceuticals And Davidoff",
    "summary": "Introduction The Delhi High Court has recently delivered two judgments underscoring how the procedural failures by the patent and trademark offices can unjustly prejudice rights. In Vertex...",
    "url": "https://finnhub.io/api/news?id=b303e90821c2dfae7ec6ea84865ee14a9cd6a927aa8d095bc97c471c69819343",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750939927,
      "headline": "Procedural Lapses In Indian IP Administration: Vertex Pharmaceuticals And Davidoff",
      "id": 135560244,
      "image": "",
      "related": "VRTX",
      "source": "Finnhub",
      "summary": "Introduction The Delhi High Court has recently delivered two judgments underscoring how the procedural failures by the patent and trademark offices can unjustly prejudice rights. In Vertex...",
      "url": "https://finnhub.io/api/news?id=b303e90821c2dfae7ec6ea84865ee14a9cd6a927aa8d095bc97c471c69819343"
    }
  },
  {
    "ts": null,
    "headline": "Victory Diversified Stock Fund Q1 2025 Commentary",
    "summary": "In the first quarter, the Victory Diversified Stock Fund A-Shares (without sales charge) underperformed its S&P 500Â®Index benchmark by 95 basis points.",
    "url": "https://finnhub.io/api/news?id=e24c741fcfd4e69f1d780d535565edcb9e22315ebcd90aa2aa6c1dbb7547c944",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750920900,
      "headline": "Victory Diversified Stock Fund Q1 2025 Commentary",
      "id": 135552014,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2149332829/image_2149332829.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "In the first quarter, the Victory Diversified Stock Fund A-Shares (without sales charge) underperformed its S&P 500Â®Index benchmark by 95 basis points.",
      "url": "https://finnhub.io/api/news?id=e24c741fcfd4e69f1d780d535565edcb9e22315ebcd90aa2aa6c1dbb7547c944"
    }
  },
  {
    "ts": null,
    "headline": "Victory Munder Multi-Cap Fund Q1 2025 Commentary",
    "summary": "Victory Munder Multi-Cap Fund Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=54acc3b2032ea85e7556dc7c5b6f6440d00ca914fdf695841f823d2c5501ecb1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750919880,
      "headline": "Victory Munder Multi-Cap Fund Q1 2025 Commentary",
      "id": 135550691,
      "image": "",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=54acc3b2032ea85e7556dc7c5b6f6440d00ca914fdf695841f823d2c5501ecb1"
    }
  }
]